Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

European Innovation Council

Investor type Incubator

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 239
Average round size
info
The average size of a deal this fund participated in
$4M
Portfolio companies 206
Rounds per year 3.62
Lead investments 41
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.14
Exits 5
Key employees Soon

Areas of investment

  • Health Care
  • Biotechnology
  • Medical Device
  • Medical
  • Software
Summary

European Innovation Council appeared to be the Corporate Investor, which was created in 1957.

We can highlight the next thriving fund investment areas, such as Computer, Information Technology. Among the various public portfolio startups of the fund, we may underline ultimate.ai, ultimate.ai, Desentum Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low.

The standard case for the fund is to invest in rounds with 1 partaker. Despite the European Innovation Council, startups are often financed by EASME - EU Executive Agency for SMEs, OurCrowd, Maki.vc. In the next rounds fund is usually obtained by Maki.vc, Horizon 2020, HV Holtzbrinck Ventures.

The common things for fund are deals in the range of 1 - 5 millions dollars. The important activity for fund was in 2019. The real fund results show that this Corporate Investor is 45 percentage points more often commits exit comparing to other companies. The fund is constantly included in 7-12 investment rounds annually.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of European Innovation Council:
Typical Co-investors
European Innovation Council is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after European Innovation Council:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Boton Belt Anhui, China, Wuxi
Brunswick Illinois, Lake Forest, United States
China Chengxin Credit Beijing, Beijing, China
Freedom Factory Studios Community of Madrid, Madrid, Spain
Freeman Spogli California, Los Angeles, United States
Gaorui Touzi China, Guangdong, Shenzhen
Hengqin Gaiya Sanhao Changwai Guquan Touzi China, Guangdong, Zhuhai
Hongyou Chuangye Touzi Chengguan District, China, Lhasa
Intelligent Fund of Funds -
Invus Opportunities -
Nanjing Shengshi Yangzi Fund Investment Management China, Jiangsu, Nanjing
National Health Forecast (PSN) -
Notus Technologies -
Pharmstandard Moscow, Moscow, Russia
Quick Heal Technologies India, Maharashtra, Pune
Shihaisong Capital -
Striim California, Palo Alto, United States
Tsukui Japan, Kanagawa Prefecture, Yokohama
Venus MedTech China, Hangzhou, Zhejiang

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Iris.ai

Advanced Materials
Artificial Intelligence
Assistive Technology
Chemical
Chemical Engineering
EdTech
Life Science
Machine Learning
Pharmaceutical
Product Research
Visual Search
$2M11 Jan 2023 Oslo, Norway

Ganymed Robotics

Robotics
$16M04 Jan 2023 Paris, Ile-de-France, France

Arctic Therapeutics

Biopharma
Biotechnology
Genetics
Medical
Pharmaceutical
Therapeutics
$14M29 Dec 2022 -

Energy Dome

Energy
Environmental Engineering
Renewable Energy
$20M22 Dec 2022 Italy, Lombardy, Italy

Sonio

Artificial Intelligence
Health Care
Medical Device
$8M21 Dec 2022 Paris, Ile-de-France, France

iOnctura

Biotechnology
Health Care
Medical Device
$17M20 Dec 2022 Geneva, Geneva, Switzerland

Tanso

Accounting
Financial Services
Software
19 Dec 2022 Munich, Bayern, Germany

ONO

Automotive
Last Mile Transportation
Logistics
Transportation
$7M06 Dec 2022 Berlin, Berlin, Germany

ROSI

Energy
Renewable Energy
Solar
$8M24 Nov 2022 Grenoble, Rhone-Alpes, France
News
Ganymed Robotics awarded a €2.5M grant from the European Commission through the EIC Accelerator Program

– Ganymed Robotics secured a €2,5M grant through the European Innovation Council Accelerator program.
– EIC Accelerator is the most competitive public funding scheme for deeptech startups in the world, with this year over 2000 companies applying and only 65 winners.
– Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.
– Ganymed’s first application is a robotic surgical assistant for total knee arthroplasties (TKA).
– Driven by a growing and aging population, demand for orthopedic surgery is rapidly increasing and the market for TKA is expected to rise from 2.4 million procedures in 2021 to 5.7 million in 2030 in the OECD alone.

EpiEndo Pharmaceuticals Secures EUR 20 Million Series A Funding to Advance Clinical Development of its Non-Antibiotic Macrolide for the treatment of COPD

– EpiEndo Pharmaceuticals announced the closing of a €20m Series A financing round.
– The round was led by Flerie Invest and Iðunn Venture Fund, with existing investors ABC Ventures participating, along with the European Innovation Council joining the round.
– The financing secures funds to advance clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication.
– EpiEndo’s development rationale is based on a newly acknowledged therapeutic paradigm, that loss of integrity of epithelial barriers plays a critical role in propagating chronic inflammatory diseases in lungs and contributes to vulnerability to infections associated with acute exacerbations of airway diseases.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent European Innovation Council?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: